| Tyrvaya (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 spray each nostril bid. Prime with 7 actuations before initial use. Re-prime with 1 actuation if not used for more than five (5) days. |
| Chem Specs | 0.6 mg/mL (0.06%) varenicline solution |
| Quantities | carton contains 2 spray bottles - 4.2ml each. (60 sprays per bottle) 0.03 mg per spray. |
| Cost | $635.71 per carton (2 bottles) |
| Class | selective cholinergic agonist partial nicotinic acetylcholine receptor agonist of α4β2, α4α6β2, α3β4, and α3α5β4 receptors and a full α7 receptor agonist. |
| Action | Activates the trigeminal parasympathetic pathway, resulting in an increased tear production. |
| Usage | Indicated for the treatment of the signs and symptoms of dry eye disease. |
| 11.5mm increase Schirmer's score compared to 4.75 for vehicle. 82% of study participants report sneezing reaction. |
|
| Contraindications | None |
| Pediatric use | Safety and efficacy of TYRVAYA in pediatric patients have not been established. |
| Pregnancy | At 4864 times normal human dose rats exhibited reduced body weight. |
| Can be used concomitantly with artificial tears. |